Molecular signaling pathways in an experimental model of Cardiorenal Syndrome

Document Type : Original articles


1 Medical Biochemistry and Molecular Biology department, Faculty of Medicine, Beni-Suef University, Egypt

2 Medical Biochemistry and Molecular Biology department kasralainy Faculty of Medicine Cairo University


The goal of this study is to investigate the role of the fibroblast growth factor 23 (FGF23) / Klotho (Klotho) molecular signaling axis in an experimental model of cardiorenal syndrome type 3 resulting from right renal artery ligation leading to renal reperfusion ischemia. The study used 12 male Wistar rats (6-8 months old, weighing 230-300g) split into 2 groups of 6 rats each (Group I, controls) and Group II, diseases, where Cardiac Hypertrophy was created as a result of renal ischemia by ligating the right renal artery. Gene expression of FGF23 and Klotho in cardiac and renal tissue was measured using quantitative real-time PCR, and blood urea and creatinine levels were measured clinically.All afflicted rats had increased amounts of creatinine in their blood, and histological analysis revealed renal ischemia and heart hypertrophy. According to real time PCR, FGF23 expression has dramatically increased in cardiac and renal tissues whereas alpha klotho expression has decreased.


Main Subjects

  1. Yap, C. & Lee, H. (2012): Acute kidney injury and extrarenal organ dysfunction: new concepts and experimental evidence. Anesthesiology; 116: 1139–1148. 
  2. Bagshaw, S., Hoste, E., Braam, B., et al. (2013): Cardiorenal Syndrome Type 3: Pathophysiologic and Epidemiologic Considerations. Contrib Nephrol.; 182: 137–157.
  3. Di Lullo, L., Bellasi, A., Barbera, V., et al. (2017): Pathophysiology of the cardio-renal syndromes types 1–5: An uptodate. Indian Heart J.; 69: 255-265. 
  4. Navarro-García, J., González-Lafuente, L., Fernández-Velasco, M., et al. (2021): Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets. Front Physiol; 12: 2042.
  5. Christov, M., Waikar, S., Pereira, R., et al. (2013): Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int; 84: 639–641.
  6. Isakova, T., Xie, H., Yang, W.,  et al. (2011): Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA; 305: 2432–2439.
  7. Da Cruz Junho, V., Caio-Silva, W., Ruiz-Hurtado, G. et al. (2019): Characterization of Klotho/FGF23 signaling in cardiorenal syndrome-induced cardiac hypertrophy. The FASEB Journal; 33: 831.1-831.1
  8. Le Clef, , Verhulst A, D’Haese PC, (2016): Unilateral Renal Ischemia-Reperfusion as a Robust Model for Acute to Chronic Kidney Injury in Mice. Plos One; 11: e0152153.
  9. Liu, X., Niu, Y., Zhang, X., et al. (2019): Recombinant α-Klotho Protein Alleviated Acute Cardiorenal Injury in a Mouse Model of Lipopolysaccharide-Induced Septic Cardiorenal Syndrome Type 5. Anal Cell Pathol (Amst); 2019: 5853426.
  10. Hao, H., Ma, S., Zheng, C., et al. (2021): Excessive fibroblast growth factor 23 promotes renal fibrosis in mice with type 2 cardiorenal syndrome. Aging (Albany NY); 13: 2982.
  11. Christov, M., Neyra, J., Gupta, S., et al. (2019): Fi-
    broblast growth factor 23 and klotho in AKI.
    Semin Nephrol; 39: 57–75.
  12. Neyra J, Hu M, Moe O,(2020): Fibroblast Growth Factor 23 and αKlotho in Acute Kidney Injury: Current Status in Diagnostic and Therapeutic Applications. Nephron; 144: 665-672.
  13. Leifheit-Nestler, M., Kirchhoff, F., Nespor, J., et al. (2018): Fibroblast growth factor 23 is induced by an activated renin–angiotensin–aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts. Nephrol. Dial. Transplant; 33: 1722–1734.
  14. Patel, R., Ning, H., de Boer, I., et al. (2020): Fibroblast Growth Factor 23 and Long-Term Cardiac Function: The Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging; 13: 11925.
  15. Almahmoud, M., Soliman, E., Bertoni, A., et al. (2018): Fibroblast growth factor-23 and heart failure with reduced versus preserved ejection fraction: MESA. J Am Heart Assoc ; 7: 
  16. Liu, E., Thoonen, R., Petit, E., et al. (2018): Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH. Endocrinology; 159: 2165–2172.
  17. Chen, K., Wang, S., Sun, W., et al. (2021): Klotho Deficiency Causes Heart Aging via Impairing the Nrf2-GR Pathway. Circ Res.; 128: 492–507.